Purpose: To assess the feasibility, efficacy, and morbidity of (125)I seeds interstitial permanent implant as salvage therapy for re-recurrent rectal cancer.
Methods And Materials: From September 2003 to October 2007, (125)I seeds implant procedures were performed under CT or ultrasound guidance for thirteen patients with locally re-recurrent rectal carcinoma. The minimal peripheral doses (MPD) of (125)I seeds implanted ranged from 120 to 160 Gy, with a median MPD of 140 Gy to total decay. Three patients also received two to four cycles of chemotherapy after seed implantation.
Results: After a median follow-up of 10 months (range 3-45), the pain-free interval was 0-14 months with a median of 7 months (95% CI: 3-11 months). The response rate of pain relief was 46.2% (6/13). Local control was 3-14 months with a median of 7 months (95% CI: 3.5-10.5 months). The 1- and 2-year local control rates were 14.4% and 0%, respectively. Three (23.1%) patients died of local recurrence; seven (53.8%) patients died of local recurrence and metastases; one (7.7%) patient died of metastases. Two (15.4%) patients survived to follow-up. At the time of analysis, the median survival was 10 months (95% CI: 3.9-16.1 months). The 1- and 2-year actuarial overall survival rates were 46.2% and 11.5%, respectively. Two (15.4%) patients experienced a grade 4 toxic event. Seed migration to the pelvic wall was observed in one (7.7%) patient. There was no associated neuropathy.
Conclusion: (125)I seed implantation is feasible, effective, and safe as a salvage or palliative treatment for patients with re-recurrent rectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00384-008-0628-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Article Synopsis
- The study retrospectively evaluated the effectiveness of ultra-low dose rate brachytherapy (uLDR-BT) in 39 patients with unfavorable intermediate risk prostate cancer, despite current guidelines recommending against it due to insufficient evidence.
- Results showed a promising median follow-up of about 56 months, with an 87.02% biochemical failure-free survival rate, indicating uLDR-BT could be a viable treatment option.
- No significant differences in outcomes were observed based on additional risk factors or treatment methods, suggesting that uLDR-BT's effectiveness is consistent across different patient profiles in the intermediate risk category.
Hydrogen-Generating Magnesium Alloy Seed Strand Sensitizes Solid Tumors to Iodine-125 Brachytherapy.
Adv Sci (Weinh)
December 2024
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Radioactive iodine-125 (I) seed implantation, a brachytherapy technique, effectively kills tumor cells via X-rays and gamma rays, serving as an alternative therapeutic option following the failure of frontline treatments for various solid tumors. However, tumor radioresistance limits its efficacy. Hydrogen gas has anticancer properties and can enhance the efficacy of immunotherapy.
View Article and Find Full Text PDFTreatment of recurrent tracheal adenoid cystic carcinoma with a covered airway stent loaded with Iodine-125 seeds: a 5-year follow-up case report.
Front Oncol
November 2024
Department of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background: The treatment of recurrent tracheal adenoid cystic carcinoma (TACC), a rare pulmonary malignant tumor, typically involves bronchoscopic interventional therapy for patients ineligible for surgery or external radiotherapy. This report describes an innovative treatment approach for TACC, initially managed with interventional bronchoscopy and subsequently with a Y-shaped airway stent loaded with I seeds, following recurrence after 2 years.
Case Presentation: A 50-year-old man presented with intermittent coughing for 2 months and was admitted to the hospital after the discovery of TACC a month earlier.
Combining transarterial chemoembolization, radiofrequency ablation, and iodine-125 seed implantation for recurrent hepatocellular carcinoma post-hepatectomy.
Diagn Interv Radiol
November 2024
Tongcheng County People's Hospital, Department of Ultrasound Medicine, Tongcheng, China.
Purpose: This study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) and iodine-125 (125I) seed implantation (TACE-RFA-125I) for recurrent hepatocellular carcinoma (HCC) after hepatectomy.
Methods: The study retrospectively analyzed patients with recurrent HCC who received TACE-RFA-125I or TACE-RFA treatment in our institution between January 2013 and January 2023. Overall survival (OS), progression-free survival (PFS), and recurrence were compared between the two groups.
A review of the efficacy and safety of iodine-125 seed implantation for lung cancer treatment.
Cancer Treat Res Commun
December 2024
Department of Respiratory and Critical Care Medicine, The First College of Clinical Medicine Science, China Three Gorges University, Yichang 443003, PR China; Department of Respiratory and Critical Care Medicine, 183 Yiling Road, Yichang Central People's Hospital, Yichang 443003, PR China; Clinical Medical Research Center for Precision Diagnosis and Treatment of Lung Cancer and Management of Advanced Cancer Pain of Hubei Province, Yichang 443003, PR China. Electronic address:
Article Synopsis
- * Radioactive iodine-125 (125-I) seed implantation therapy, known as brachytherapy, has shown promise by placing radioactive seeds directly into tumors, allowing targeted cancer cell destruction while protecting surrounding healthy tissue.
- * The review highlights the effectiveness and safety of 125-I brachytherapy alone or in combination with other treatments for lung cancer, but emphasizes the need for standardized dosing and protocols to improve treatment consistency and patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!